Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Leukemia, Myeloid, Acute 2Glioma 2Glioblastoma 2Cholangiocarcinoma 2Spinal Cord Neoplasms 1Oligodendroglioma 1Neoplasms 1Myelodysplastic Syndromes 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Gemcitabine 11Cisplatin 10pembrolizumab 7Fluorouracil 3Drug Therapy 3spartalizumab 2derazantinib 2Leucovorin 2trametinib 1tislelizumab 1silmitasertib 1seribantumab 1pertuzumab 1olutasidenib 1galactomannan 1exatecan 1durvalumab 1becatecarin 1Tegafur 1Standard of Care 1S 1 (combination) 1Ritonavir 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Observation 1Nivolumab 1Molecular Diagnostic Techniques 1Microscopy, Confocal 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bile Duct Neoplasms × olutasidenib × Clear all
NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡